TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00723606
Drug: Intramuscular ziprasidone mesylate
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
Study: NCT00723606
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
Study: NCT00040040
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04073316
Drug: Rivaroxaban 20 MG
Normalized name: rivaroxaban 20 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban intake, 20mg/day
Study: NCT04073316
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin intake, with target INR range between 2 and 3
Study: NCT00080847
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02465528
Drug: Ceritinib (LDK378)
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
Study: NCT01790464
Drug: 2% Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
Study: NCT01567488
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg/day
Study: NCT01567488
Drug: octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg each 28 days
Study: NCT04598542
Drug: Lorecivivint (LOR)
Normalized name: Lorecivivint
DrugBank: Lorecivivint (DB14883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg
Study: NCT04598542
Drug: Triamcinolone acetonide (TA)
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg
Study: NCT03460522
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
Study: NCT00117143
Drug: Romiplostim
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
Study: NCT01148953
Drug: ALN-TTR01
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
Study: NCT01148953
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match active comparator
Study: NCT02719158
Drug: 6 mg ciprofloxacin
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of OTO-201
Study: NCT02719158
Drug: 12 mg ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of OTO-201
Study: NCT00006484
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006484
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00006484
Drug: tirapazamine
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03929965
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib
Study: NCT00876304
Drug: PF-04802540
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
Study: NCT04354428
Drug: Hydroxychloroquine Sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy
Study: NCT02825836
Drug: TL-895
Normalized name: TL-895
DrugBank: TL-895 (DB16471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
Study: NCT02825836
Drug: Navtemadlin
Normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
Study: NCT00386412
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
Study: NCT04974970
Drug: Peanut Immunotherapy
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
Study: NCT01331694
Drug: fluticasone/salmeterol combination (FSC) 250/50mcg
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
Study: NCT01331694
Drug: tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients initiating treatment with tiotropium
Study: NCT01331694
Drug: ipratropium bromide alone or in fixed dose combination with albuterol
Normalized name: albuterol / ipratropium bromide Inhalation Solution
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients initiating treatment with ipratropium/albuterol
Study: NCT03846258
Drug: Low bicarbonate solution (22 mmol/L)
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
Study: NCT03846258
Drug: High Bicarbonate solution (32 mmol/L)
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
Study: NCT02022228
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 mg triptorelin, ih
Study: NCT02022228
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU hCG, im
Study: NCT02022228
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500IU hCG, im
Study: NCT01188603
Drug: flibanserin 100 mg dose every evening
Normalized name: flibanserin 100 MG
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all subjects receive flibanserin
Study: NCT03012386
Drug: Sildenafil Citrate in G allele carrier
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chronic use of phosphodiesterase 5 inhibitor in G allele carrier
Study: NCT03012386
Drug: Sildenafil Citrate in non G allele carrier
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
Study: NCT04292730
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an intravenous infusion
Study: NCT04565054
Drug: Abemaciclib 50 MG; 150mg 1-0-1 per os
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
Study: NCT04354428
Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Normalized name: lopinavir 200 MG / ritonavir 50 MG [Kaletra]
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
Study: NCT02582099
Drug: Normal saline nasal irrigation
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal wash with normal saline solution
Study: NCT03143270
Drug: Drug Eluting Bead Transarterial Chemoembolization
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
Study: NCT03143270
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
Study: NCT02269462
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
Study: NCT02269462
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
Study: NCT02102633
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg orally
Study: NCT02102633
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 500 mg orally
Study: NCT03367312
Drug: Hyperpolarized 129Xenon gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
Study: NCT01226719
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg/kg, 60-90 minute IV infusion every 2 weeks
Study: NCT01226719
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2, 2-hour IV infusion every 2 weeks
Study: NCT01226719
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 125 mg/m2, 1-hour IV infusion every 2 weeks
Study: NCT01226719
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3200 mg/m2 IV, 48-hour continuous infusion every two weeks
Study: NCT00768729
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
Study: NCT01760148
Drug: interferon alpha 2b
Normalized name: PEGINTERFERON ALPHA 2B 80MCG/0.5ML INJ,KIT
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.
Study: NCT02457325
Drug: Surgery with 2%Articaine first, then Surgery with 4% Articaine
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
Study: NCT02457325
Drug: Surgery with 4%Articaine first, then Surgery with 2% Articaine
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
Study: NCT01374308
Drug: Pegylated interferon alpha 2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
Study: NCT01302821
Drug: 1-methyl-D-tryptophan
Normalized name: 1-methyl-D-tryptophan
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
Study: NCT02501096
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
Study: NCT02501096
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
Study: NCT00516373
Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01510327
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Study: NCT00053794
Drug: perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03759067
Drug: clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel once daily 75mg
Study: NCT03759067
Drug: Clopidogrel 300 mg
Normalized name: clopidogrel 300 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 300mg reloading
Study: NCT03759067
Drug: clopidogrel 600mg
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 600mg loading
Study: NCT01510327
Drug: Thienopyridine
Normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study: NCT04037774
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparision of different doses of dexmedetomidine used intrathecally
Study: NCT01574703
Drug: varenicline tartrate
Normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing to have taken place per study A3051123
Study: NCT01574703
Drug: bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing to have taken place per study A3051123
Study: NCT01574703
Drug: Nicotine Replacement Therapy Patch
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing to have taken place per study A3051123
Study: NCT04659785
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
Study: NCT04659785
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
Study: NCT01458327
Drug: Midomafetamine
Normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
Study: NCT00122720
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01639027
Drug: Drotaverine
Normalized name: drotaverine
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
Study: NCT03561402
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each patient will receive 1 tablet (14 mg) on a daily basis.
Study: NCT01886248
Drug: Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01703637
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy
Study: NCT01703637
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: * before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy
Study: NCT01703637
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy
Study: NCT01831232
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01831232
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01737931
Drug: Topical steroid (Dexamethasone)
Normalized name: dexamethasone Topical Solution
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
Study: NCT00974714
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine 2 g twice a day for 14 weeks
Study: NCT02201303
Drug: Danirixin
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered form for in-vitro administration to blood sample
Study: NCT01153581
Drug: Ganirelix acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix acetate: .25 ml/day by subcutaneous injection
Study: NCT01153581
Drug: 17β-Oestradiol
Normalized name: 17β-oestradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17 beta estradiol: 0.2 mg/day (patches)
Study: NCT01153581
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: progesterone, 200 mg day-1 oral
Study: NCT01399593
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03765294
Drug: ACT-541468
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet for oral use